Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2014-A00938-39 | Other Identifier | 2014-A00938-39 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
The loss of muscle mass in chronic heart failure patients is a prognostic factor for sarcopenia. The purpose was to identify in these patients signs of sarcopenia for a better management.
Age-related muscle loss, termed sarcopenia, affects 10% of elderly subjects aged 60-70 years and more than 30% above the age of 80. The concept of sarcopenia has been supported by the recent findings of muscular atrophy which was related to the decrease of protein synthesis because of the "anabolic resistance", affecting the muscular fibers type II. In fact, sarcopenia could be a consequence of chronic disease and not only an issue in the elderly people. The diagnosis is assessed by the weak muscle mass and the muscle strength and function. A description of these muscle parameters has been described in a study of 200 patients with NYHA class II-III and showed that 19,5 % have a decrease in muscle mass. They also showed that these patients have a lower functional ability. These findings prompted us to investigate the prevalence of sarcopenia in chronic heart failure subjects for a better management of these patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Heart failure patients | Experimental | The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. |
|
| TAVI patients | Experimental | The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Assessment of sarcopenia prevalence | Diagnostic Test | Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test |
| Measure | Description | Time Frame |
|---|---|---|
| Bioimpedance analysis data | Fat-free mass and body fat mass will be combined to report BMI in Kg/m2 | at day 1 |
| Short physical performance battery | Balance test, 4-min walking test, 5 times getting-up test | at day 1 |
| Handgrip test | at day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Blood draw for serum creatinine in umol/L | Measure of inflammation | at day 1 |
| CRP in mg/L | Measure of inflammation | at day 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Patrick LACARIN | Contact | 04 73 75 11 95 | placarin@chu-clermontferand.fr | |
| Romain ESCHALIER, PhD | Contact | 0033 473 751 410 | reschalier@chu-clermontferrand.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Clermont-Ferrand | Recruiting | Clermont-Ferrand | Auvergne | 63003 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35871922 | Derived | Blanquet M, Massoulie G, Boirie Y, Guiguet-Auclair C, Mulliez A, Anker S, Boiteux MD, Jean F, Combaret N, Souteyrand G, Riocreux C, Pereira B, Motreff P, Rossignol P, Clerfond G, Eschalier R. Handgrip strength to screen early-onset sarcopenia in heart failure. Clin Nutr ESPEN. 2022 Aug;50:183-190. doi: 10.1016/j.clnesp.2022.05.019. Epub 2022 Jun 6. | |
| 33483182 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D055948 | Sarcopenia |
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Open
Not provided
|
| platelets in Giga/L | Measure of inflammation | at day 1 |
| complete blood count CBC (white blood cells in Giga/L and red blood cells in Tera/L) | Measure of inflammation | at day 1 |
| urea in mmol/L | Measure of inflammation | at day 1 |
| albumin in g/L | Measure of inflammation | at day 1 |
| NT-ProBNP in ng/L | Measure of inflammation | at day 1 |
| Electrocardiogram | Parameter which may interfere with sarcopenia | at day 1 |
| Trans-thoracic echography | Parameter which may interfere with sarcopenia | at day 1 |
| Eschalier R, Massoullie G, Boirie Y, Blanquet M, Mulliez A, Tartiere PL, Anker S, D'Agrosa Boiteux MC, Richard R, Jean F, Combaret N, Souteyrand G, Riocreux C, Pereira B, Motreff P, Stolt P, Rossignol P, Clerfond G. Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact. Clin Nutr. 2021 Jun;40(6):4490-4499. doi: 10.1016/j.clnu.2020.12.033. Epub 2021 Jan 9. |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |